ZA200903652B - Methods for treating disruptive behavior disorders - Google Patents
Methods for treating disruptive behavior disordersInfo
- Publication number
- ZA200903652B ZA200903652B ZA200903652A ZA200903652A ZA200903652B ZA 200903652 B ZA200903652 B ZA 200903652B ZA 200903652 A ZA200903652 A ZA 200903652A ZA 200903652 A ZA200903652 A ZA 200903652A ZA 200903652 B ZA200903652 B ZA 200903652B
- Authority
- ZA
- South Africa
- Prior art keywords
- disruptive behavior
- behavior disorders
- methods
- disorder
- therapy
- Prior art date
Links
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 title abstract 5
- 208000035548 disruptive behavior disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000027691 Conduct disease Diseases 0.000 abstract 2
- 208000024196 oppositional defiant disease Diseases 0.000 abstract 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract 1
- 238000011262 co‐therapy Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86313706P | 2006-10-27 | 2006-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200903652B true ZA200903652B (en) | 2010-08-25 |
Family
ID=39469514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200903652A ZA200903652B (en) | 2006-10-27 | 2009-05-26 | Methods for treating disruptive behavior disorders |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20080103127A1 (es) |
| EP (1) | EP2089015B1 (es) |
| JP (1) | JP2010508279A (es) |
| KR (1) | KR20090088379A (es) |
| CN (1) | CN101646432A (es) |
| AT (1) | ATE489083T1 (es) |
| AU (1) | AU2007329779A1 (es) |
| BR (1) | BRPI0718318A2 (es) |
| CA (1) | CA2667510A1 (es) |
| CO (1) | CO6160292A2 (es) |
| DE (1) | DE602007010818D1 (es) |
| EA (1) | EA015690B1 (es) |
| ES (1) | ES2354319T3 (es) |
| IL (1) | IL198396A0 (es) |
| MX (1) | MX2009004552A (es) |
| NO (1) | NO20091659L (es) |
| SV (1) | SV2009003241A (es) |
| WO (1) | WO2008070277A2 (es) |
| ZA (1) | ZA200903652B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| JOP20120083B1 (ar) * | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| CN113993523A (zh) | 2019-04-17 | 2022-01-28 | 指南针探路者有限公司 | 用赛洛西宾治疗抑郁症和其他各种病症 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| EA006598B1 (ru) * | 1999-08-20 | 2006-02-24 | Орто-Макнейл Фармасьютикал, Инк. | Композиция, содержащая трамадол и противосудорожное лекарственное средство |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| MXPA03007720A (es) * | 2001-02-27 | 2004-11-12 | Johnson & Johnson | Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos de ansiedad. |
-
2007
- 2007-10-11 EP EP07871150A patent/EP2089015B1/en active Active
- 2007-10-11 CA CA002667510A patent/CA2667510A1/en not_active Abandoned
- 2007-10-11 AT AT07871150T patent/ATE489083T1/de not_active IP Right Cessation
- 2007-10-11 CN CN200780048441A patent/CN101646432A/zh active Pending
- 2007-10-11 EA EA200970425A patent/EA015690B1/ru not_active IP Right Cessation
- 2007-10-11 ES ES07871150T patent/ES2354319T3/es active Active
- 2007-10-11 WO PCT/US2007/081048 patent/WO2008070277A2/en not_active Ceased
- 2007-10-11 DE DE602007010818T patent/DE602007010818D1/de active Active
- 2007-10-11 KR KR1020097010725A patent/KR20090088379A/ko not_active Withdrawn
- 2007-10-11 BR BRPI0718318-6A patent/BRPI0718318A2/pt not_active IP Right Cessation
- 2007-10-11 JP JP2009534756A patent/JP2010508279A/ja not_active Withdrawn
- 2007-10-11 MX MX2009004552A patent/MX2009004552A/es active IP Right Grant
- 2007-10-11 AU AU2007329779A patent/AU2007329779A1/en not_active Abandoned
- 2007-10-11 US US11/870,589 patent/US20080103127A1/en not_active Abandoned
-
2009
- 2009-04-26 IL IL198396A patent/IL198396A0/en unknown
- 2009-04-27 NO NO20091659A patent/NO20091659L/no not_active Application Discontinuation
- 2009-04-27 SV SV2009003241A patent/SV2009003241A/es not_active Application Discontinuation
- 2009-04-29 CO CO09043278A patent/CO6160292A2/es unknown
- 2009-05-26 ZA ZA200903652A patent/ZA200903652B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008070277A2 (en) | 2008-06-12 |
| EP2089015A2 (en) | 2009-08-19 |
| MX2009004552A (es) | 2009-11-10 |
| AU2007329779A1 (en) | 2008-06-12 |
| WO2008070277A3 (en) | 2008-08-07 |
| US20080103127A1 (en) | 2008-05-01 |
| CN101646432A (zh) | 2010-02-10 |
| EA015690B1 (ru) | 2011-10-31 |
| EP2089015B1 (en) | 2010-11-24 |
| CA2667510A1 (en) | 2008-06-12 |
| KR20090088379A (ko) | 2009-08-19 |
| ATE489083T1 (de) | 2010-12-15 |
| ES2354319T3 (es) | 2011-03-14 |
| JP2010508279A (ja) | 2010-03-18 |
| BRPI0718318A2 (pt) | 2013-11-26 |
| CO6160292A2 (es) | 2010-05-20 |
| EA200970425A1 (ru) | 2009-12-30 |
| DE602007010818D1 (de) | 2011-01-05 |
| NO20091659L (no) | 2009-05-26 |
| IL198396A0 (en) | 2010-02-17 |
| SV2009003241A (es) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200602048A (en) | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase | |
| WO2008022024A3 (en) | Imidazole amines as inhibitors of beta-secretase | |
| EA200601746A1 (ru) | Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс" | |
| WO2007137164A3 (en) | Co-therapy for the treatment of epilepsy and related disorders | |
| BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| ZA200810113B (en) | Method for the treatment and prevention of ocular disorders | |
| WO2006113942A3 (en) | Method of inhibiting cathepsin activity | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| MX2009004798A (es) | Tratamiento de los trastornos generalizados del desarrollo. | |
| WO2007112345A8 (en) | Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders | |
| BRPI0510094A (pt) | uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos | |
| SI2205244T1 (sl) | Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni | |
| WO2007112357A3 (en) | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders | |
| WO2012002687A3 (en) | Methods for treating bipolar disorder | |
| MX2009004770A (es) | Compuestos de carbamato para usarse en el tratamiento de la depresion. | |
| EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
| BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
| ZA200903652B (en) | Methods for treating disruptive behavior disorders | |
| WO2007136741A3 (en) | N-desmethyl-doxepin and methods of using the same to treat sleep disorders | |
| NZ606276A (en) | Fastening Means | |
| WO2010019701A3 (en) | Diaryl urea derivatives | |
| WO2010005585A3 (en) | 4-aminoquinazoline prodrugs | |
| WO2009131850A3 (en) | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |